Repligen Corp (RGEN)

Industry Medical Instruments & Supplies
This stock can be held in an Investment ISA and an Investment Account
Sell

$80.00

Buy

$150.00

arrow-up$1.14 (+0.94%)

Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.
Prices updated at 29 May 2025, 21:04 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.39%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Chairman
Mr. Tony J. Hunt
CEO
Mr. Olivier Loeillot
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,778
Head office
41 Seyon Street
Waltham
United States
02453
mobile
+1 781 250-0111
letter
investors@repligen.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Glenn P. Muir
Independent Director
0.10m--0.34m-
Ms. Karen A. Dawes, M.A.
Lead Independent Director
0.16m--0.43m-
Mr. Nicolas M. Barthelemy
Independent Director
0.09m--0.32m-
Dr. Martin D. Madaus,PhD
Independent Director
0.08m--0.32m-
Mr. Tony J. Hunt
Executive Chairman of the Board
0.73m--20.30m-
Ms. Carrie Eglinton Manner
Independent Director
0.07m--0.31m-
Mr. Ralf Kuriyel, PhD
Senior Vice President, Research and Development
0.40m--1.99m-
Mr. Jason K. Garland
Chief Financial Officer and Principal Accounting Officer
0.55m--2.11m-
Dr. Rohin Mhatre, PhD
Independent Director
0.07m--0.31m-
Dr. Konstantin Konstantinov, PhD
Independent Director
0.07m--0.30m-
Mr. James R. Bylund
Chief Operating Officer
0.47m--4.17m-
Mr. Olivier Loeillot
Director, President and Chief Executive Officer
0.65m--7.18m-
Ms. Margaret A. Pax
Independent Director
0.05m--0.54m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
T. Rowe Price Associates, Inc.7,566,0930.118624300396.02628630 Apr 202513.47
BlackRock Inc6,815,6870.01822-41573-0.60626330 Apr 202512.13
T Rowe Price Associates, Inc6,392,245-2732754.46602930 Apr 202511.41
Vanguard Group Inc5,079,8940.01169-21196-0.41551930 Apr 20259.04
BlackRock Fund Advisors3,193,0135.78133-132083-30 Apr 20255.68

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
05 Dec 2024-Mr. Tony J. Hunt33.87399,937151,648--
05 Dec 2024-Mr. Tony J. Hunt--8,856--
21 Nov 2024-Mr. Tony J. Hunt-----
21 Nov 2024-Mr. Tony J. Hunt139.673,386,439139,840--
21 Nov 2024-Mr. Tony J. Hunt33.87821,212164,086--
20 Nov 2024-Mr. Jason K. Garland123.4145,2917,676--
20 Nov 2024-Mr. Olivier Loeillot123.41106,25632,556--
19 Nov 2024-Mr. Glenn P. Muir-----
19 Nov 2024-Mr. Glenn P. Muir36.29689,51032,283--
10 Sep 2024-Mr. Tony J. Hunt143.77214,936160,536--
10 Sep 2024-Mr. Tony J. Hunt--24,246--
10 Sep 2024-Mr. Tony J. Hunt146.6788,589139,840--
10 Sep 2024-Mr. Tony J. Hunt145.951,565,022140,444--
10 Sep 2024-Mr. Tony J. Hunt144.881,357,381151,167--
10 Sep 2024-Mr. Tony J. Hunt33.87338,700162,031--
03 Sep 2024-Mr. Tony J. Hunt--6,528--
03 Sep 2024-Mr. Tony J. Hunt--152,031--
03 Sep 2024-Mr. Olivier Loeillot--33,417--
03 Sep 2024-Mr. Olivier Loeillot--16,278--
02 Aug 2024-Mr. Ralf Kuriyel, PhD158.8527,79912,288--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.